Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (11-20 of 196) with videos related to

Pageof 20
Sort By:
Seminars in Thrombosis and Hemostasis|October 1, 1984
Laboratory application of radioimmunoassay in the quantitation of molecular markers of hemostatic activationJ M Walenga, J Fareed, D Hoppensteadt
Seminars in Thrombosis and Hemostasis|April 1, 1989
Antithrombotic drugs in pelvic surgeryJ Fareed, J M Walenga, U Cornelli
Thrombosis Research. Supplement|January 1, 1991
Laboratory monitoring of the clinical effects of low molecular weight heparinsJ M Walenga, D Hoppensteadt, J Fareed
Journal of Pharmaceutical Sciences|September 1, 1988
Aggregates in heparinE Coyne, J M Walenga, J Fareed
Drugs & Aging|September 1, 1992
Low molecular weight heparins. An objective overviewD Hoppensteadt, J M Walenga, J Fareed
Thrombosis Research|November 1, 1990
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparinD Hoppensteadt, J M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1984
Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide AJ Amiral, J M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1991
Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspectiveJ M Walenga, D Hoppensteadt, J Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1993
Current perspectives on low molecular weight heparinsJ Fareed, D A Hoppensteadt, J M Walenga
Seminars in Thrombosis and Hemostasis|October 1, 1984
Molecular markers of platelet activationH L Messmore, J M Walenga, J Fareed
Pageof 20

Showing results (11-20 of 196) with videos related to

Sort By:
Pageof 20
Seminars in Thrombosis and Hemostasis|October 1, 1984
Laboratory application of radioimmunoassay in the quantitation of molecular markers of hemostatic activationJ M Walenga, J Fareed, D Hoppensteadt
Seminars in Thrombosis and Hemostasis|April 1, 1989
Antithrombotic drugs in pelvic surgeryJ Fareed, J M Walenga, U Cornelli
Thrombosis Research. Supplement|January 1, 1991
Laboratory monitoring of the clinical effects of low molecular weight heparinsJ M Walenga, D Hoppensteadt, J Fareed
Journal of Pharmaceutical Sciences|September 1, 1988
Aggregates in heparinE Coyne, J M Walenga, J Fareed
Drugs & Aging|September 1, 1992
Low molecular weight heparins. An objective overviewD Hoppensteadt, J M Walenga, J Fareed
Thrombosis Research|November 1, 1990
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparinD Hoppensteadt, J M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|October 1, 1984
Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide AJ Amiral, J M Walenga, J Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1991
Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspectiveJ M Walenga, D Hoppensteadt, J Fareed
Seminars in Thrombosis and Hemostasis|January 1, 1993
Current perspectives on low molecular weight heparinsJ Fareed, D A Hoppensteadt, J M Walenga
Seminars in Thrombosis and Hemostasis|October 1, 1984
Molecular markers of platelet activationH L Messmore, J M Walenga, J Fareed
Pageof 20